Cargando…
Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is rapidly acquiring new mutations. Analysis of these mutations is necessary for gaining knowledge regarding different aspects of therapeutic development. Previously,...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017899/ https://www.ncbi.nlm.nih.gov/pubmed/33797663 http://dx.doi.org/10.1186/s43141-021-00152-z |
_version_ | 1783674138928349184 |
---|---|
author | Hossain, Mohammad Uzzal Bhattacharjee, Arittra Emon, Md. Tabassum Hossain Chowdhury, Zeshan Mahmud Ahammad, Ishtiaque Mosaib, Md. Golam Moniruzzaman, Md. Rahman, Md. Hadisur Islam, Md. Nazrul Ahmed, Irfan Amin, Md. Ruhul Rashed, Asif Das, Keshob Chandra Keya, Chaman Ara Salimullah, Md. |
author_facet | Hossain, Mohammad Uzzal Bhattacharjee, Arittra Emon, Md. Tabassum Hossain Chowdhury, Zeshan Mahmud Ahammad, Ishtiaque Mosaib, Md. Golam Moniruzzaman, Md. Rahman, Md. Hadisur Islam, Md. Nazrul Ahmed, Irfan Amin, Md. Ruhul Rashed, Asif Das, Keshob Chandra Keya, Chaman Ara Salimullah, Md. |
author_sort | Hossain, Mohammad Uzzal |
collection | PubMed |
description | BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is rapidly acquiring new mutations. Analysis of these mutations is necessary for gaining knowledge regarding different aspects of therapeutic development. Previously, we have reported a Sanger method-based genome sequence of a viral isolate named SARS-CoV-2 NIB-1, circulating in Bangladesh. The genome has four novel non-synonymous mutations in V121D, V843F, A889V, and G1691C positions. RESULTS: Using different computational tools, we have found V121D substitution has the potential to destabilize the non-structural protein-1 (NSP-1). NSP-1 inactivates the type-1 interferon-induced antiviral system. Hence, this mutant could be a basis of attenuated vaccines against SARS-CoV-2. V843F, A889V, and G1691C are all located in nonstructural protein-3 (NSP-3). G1691C can decrease the flexibility of the protein. V843F and A889V might change the binding pattern and efficacy of SARS-CoV-2 papain-like protease (PLPro) inhibitor GRL0617. V843F substitution in PLPro was the most prevalent mutation in the clinical samples. This mutation showed a reduced affinity for interferon-stimulated gene-15 protein (ISG-15) and might have an impact on innate immunity and viral spread. However, V843F+A889V double mutant exhibited the same binding affinity as wild type PLPro. A possible reason behind this phenomenon can be that V843F is a conserved residue of PLPro which damaged the protease structure, but A889V, a less conserved residue, presumably neutralized that damage. CONCLUSIONS: Mutants of NSP-1 could provide attenuated vaccines against coronavirus. Also, these mutations of PLPro might be targeted to develop better anti-SARS therapeutics. We hope our study will help to get better insides during the development of attenuated vaccine and PLPro inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-021-00152-z. |
format | Online Article Text |
id | pubmed-8017899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80178992021-04-06 Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics Hossain, Mohammad Uzzal Bhattacharjee, Arittra Emon, Md. Tabassum Hossain Chowdhury, Zeshan Mahmud Ahammad, Ishtiaque Mosaib, Md. Golam Moniruzzaman, Md. Rahman, Md. Hadisur Islam, Md. Nazrul Ahmed, Irfan Amin, Md. Ruhul Rashed, Asif Das, Keshob Chandra Keya, Chaman Ara Salimullah, Md. J Genet Eng Biotechnol Research BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), is rapidly acquiring new mutations. Analysis of these mutations is necessary for gaining knowledge regarding different aspects of therapeutic development. Previously, we have reported a Sanger method-based genome sequence of a viral isolate named SARS-CoV-2 NIB-1, circulating in Bangladesh. The genome has four novel non-synonymous mutations in V121D, V843F, A889V, and G1691C positions. RESULTS: Using different computational tools, we have found V121D substitution has the potential to destabilize the non-structural protein-1 (NSP-1). NSP-1 inactivates the type-1 interferon-induced antiviral system. Hence, this mutant could be a basis of attenuated vaccines against SARS-CoV-2. V843F, A889V, and G1691C are all located in nonstructural protein-3 (NSP-3). G1691C can decrease the flexibility of the protein. V843F and A889V might change the binding pattern and efficacy of SARS-CoV-2 papain-like protease (PLPro) inhibitor GRL0617. V843F substitution in PLPro was the most prevalent mutation in the clinical samples. This mutation showed a reduced affinity for interferon-stimulated gene-15 protein (ISG-15) and might have an impact on innate immunity and viral spread. However, V843F+A889V double mutant exhibited the same binding affinity as wild type PLPro. A possible reason behind this phenomenon can be that V843F is a conserved residue of PLPro which damaged the protease structure, but A889V, a less conserved residue, presumably neutralized that damage. CONCLUSIONS: Mutants of NSP-1 could provide attenuated vaccines against coronavirus. Also, these mutations of PLPro might be targeted to develop better anti-SARS therapeutics. We hope our study will help to get better insides during the development of attenuated vaccine and PLPro inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43141-021-00152-z. Springer Berlin Heidelberg 2021-04-02 /pmc/articles/PMC8017899/ /pubmed/33797663 http://dx.doi.org/10.1186/s43141-021-00152-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Hossain, Mohammad Uzzal Bhattacharjee, Arittra Emon, Md. Tabassum Hossain Chowdhury, Zeshan Mahmud Ahammad, Ishtiaque Mosaib, Md. Golam Moniruzzaman, Md. Rahman, Md. Hadisur Islam, Md. Nazrul Ahmed, Irfan Amin, Md. Ruhul Rashed, Asif Das, Keshob Chandra Keya, Chaman Ara Salimullah, Md. Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics |
title | Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics |
title_full | Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics |
title_fullStr | Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics |
title_full_unstemmed | Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics |
title_short | Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics |
title_sort | novel mutations in nsp-1 and plpro of sars-cov-2 nib-1 genome mount for effective therapeutics |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017899/ https://www.ncbi.nlm.nih.gov/pubmed/33797663 http://dx.doi.org/10.1186/s43141-021-00152-z |
work_keys_str_mv | AT hossainmohammaduzzal novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT bhattacharjeearittra novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT emonmdtabassumhossain novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT chowdhuryzeshanmahmud novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT ahammadishtiaque novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT mosaibmdgolam novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT moniruzzamanmd novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT rahmanmdhadisur novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT islammdnazrul novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT ahmedirfan novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT aminmdruhul novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT rashedasif novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT daskeshobchandra novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT keyachamanara novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics AT salimullahmd novelmutationsinnsp1andplproofsarscov2nib1genomemountforeffectivetherapeutics |